Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Delta-1 enhances marrow and thymus repopulating ability of human CD34+CD38– cord blood cells
Kohshi Ohishi, … , Barbara Varnum-Finney, Irwin D. Bernstein
Kohshi Ohishi, … , Barbara Varnum-Finney, Irwin D. Bernstein
Published October 15, 2002
Citation Information: J Clin Invest. 2002;110(8):1165-1174. https://doi.org/10.1172/JCI16167.
View: Text | PDF
Article Stem cells

Delta-1 enhances marrow and thymus repopulating ability of human CD34+CD38– cord blood cells

  • Text
  • PDF
Abstract

Research Article

Authors

Kohshi Ohishi, Barbara Varnum-Finney, Irwin D. Bernstein

×

Figure 4

Options: View larger image (or click on image) Download as PowerPoint
I-Delta1ext-myc enhances engraftment of human cells in marrow of NOD/SCI...
I-Delta1ext-myc enhances engraftment of human cells in marrow of NOD/SCID β2m–/– or NOD/SCID mice. (a and b) We transplanted 4.7 × 103 fresh CD34+CD38– cells along with 2 × 106 irradiated (15 Gy) CD34– cord blood cells (day 0), or all the progeny of 4.7 × 103 CD34+CD38– cells cultured for 16, 23, or 29 days with Delta1ext-myc (I-Delta) or control medium (Control), into sublethally irradiated NOD/SCID β2–/– mice (n = 7). At 3 and 6 weeks, marrow was aspirated from both knee joints (a), and at 9 weeks, mice were sacrificed and marrow was harvested from both femurs and both tibiae (b). We assessed human cell engraftment by counting the number of cells, in aspirated marrow, that stained with Peridinin chloropyll protein–conjucated (PerCP-conjugated) anti–human CD45 and PE-conjugated anti–human CD33, CD19, or CD34, excluding cells staining with FITC-conjugated anti–mouse CD45.1 and DAPI-staining dead cells (see Methods). Mean (± SEM) engraftment of human cells in mice in each group is shown. Data are representative of four different experiments. (c) We transplanted 5 × 103 fresh CD34+CD38– cells along with 2 × 106 irradiated (15 Gy) CD34– cord blood cells (Noncultured), or all the progeny of 5 × 103 CD34+CD38– cells cultured for 21 days with I-Delta1ext-myc (I-Delta) or control medium (Control), into sublethally irradiated NOD/SCID mice (n = 10). At 3 and 6 weeks, marrow was aspirated from both knee joints, and at 12 weeks, mice were sacrificed and marrow was harvested from both femurs and both tibiae. Mean percentage (± SEM) of human cells in marrow is shown.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts